Novo Nordisk to test weight-loss drugs in broader range of obesity-linked conditions

Novo Nordisk is broadening its focus beyond obesity and diabetes by exploring the potential of its weight-loss drugs, including Wegovy, to treat conditions like knee osteoarthritis and sleep apnea. Clinical trials are planned to investigate the impact of CagriSema and amycretin on various obesity-related comorbidities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/js6zR2W
via IFTTT